Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
An announcement from Q-linea AB ( (SE:QLINEA) ) is now available.
Q-linea has been selected to supply its ASTar rapid antimicrobial susceptibility testing system to several Italian laboratories to meet tender obligations following the market withdrawal of the Accelerate Pheno rapid AST system. The company is working closely with affected labs to ensure a swift transition, with customers citing ASTar’s ease of use, broad organism and antibiotic coverage, and high-throughput capabilities, and Q-linea is also assessing additional demand from former Pheno users seeking a reliable replacement solution.
The most recent analyst rating on (SE:QLINEA) stock is a Sell with a SEK23.00 price target. To see the full list of analyst forecasts on Q-linea AB stock, see the SE:QLINEA Stock Forecast page.
More about Q-linea AB
Q-linea AB is a Sweden-based medical technology company specializing in rapid antimicrobial susceptibility testing (rAST) for bloodstream infections and sepsis. Its flagship CE-IVD-marked and FDA 510(k)-cleared ASTar system is used in hospitals to significantly reduce time to optimal antimicrobial therapy, supporting more effective treatment decisions and promoting sustainable antibiotic use. Headquartered in Uppsala with regional offices in Italy and the US, Q-linea operates through a global network of partnerships.
YTD Price Performance: -75.47%
Average Trading Volume: 11,295
Technical Sentiment Signal: Sell
Current Market Cap: SEK416.4M
Learn more about QLINEA stock on TipRanks’ Stock Analysis page.